Johnson & Johnson (JNJ) – Investment Analysts’ Recent Ratings Updates

Johnson & Johnson (NYSE: JNJ) recently received a number of ratings updates from brokerages and research firms:

• 2/3/2026 – Johnson & Johnson had its price target raised by analysts at Royal Bank Of Canada from $240.00 to $255.00. They now have an “outperform” rating on the stock.
• 1/30/2026 – Johnson & Johnson had its price target raised by analysts at HSBC Holdings plc from $240.00 to $265.00. They now have a “buy” rating on the stock.
• 1/29/2026 – Johnson & Johnson had its price target raised by analysts at Daiwa Securities Group Inc. from $203.00 to $237.00. They now have an “outperform” rating on the stock.
• 1/28/2026 – Johnson & Johnson had its “buy (b)” rating reaffirmed by analysts at Weiss Ratings.
• 1/28/2026 – Johnson & Johnson was given a new $262.00 price target on by analysts at Morgan Stanley. They now have an “overweight” rating on the stock.
• 1/27/2026 – Johnson & Johnson was given a new $220.00 price target on by analysts at Loop Capital.
• 1/25/2026 – Johnson & Johnson was upgraded by analysts at Wall Street Zen from a “hold” rating to a “buy” rating.
• 1/23/2026 – Johnson & Johnson had its price target raised by analysts at Guggenheim from $227.00 to $240.00. They now have a “buy” rating on the stock.
• 1/23/2026 – Johnson & Johnson had its price target raised by analysts at Argus from $210.00 to $240.00.
• 1/23/2026 – Johnson & Johnson had its price target raised by analysts at Sanford C. Bernstein from $208.00 to $225.00. They now have a “market perform” rating on the stock.
• 1/22/2026 – Johnson & Johnson had its “outperform” rating reaffirmed by analysts at Scotiabank.
• 1/22/2026 – Johnson & Johnson had its price target raised by analysts at TD Cowen from $222.00 to $250.00. They now have a “buy” rating on the stock.
• 1/22/2026 – Johnson & Johnson had its price target raised by analysts at Morgan Stanley from $197.00 to $200.00. They now have an “equal weight” rating on the stock.
• 1/22/2026 – Johnson & Johnson had its “buy” rating reaffirmed by analysts at The Goldman Sachs Group, Inc.. They now have a $250.00 price target on the stock.
• 1/22/2026 – Johnson & Johnson had its price target raised by analysts at Citigroup Inc. from $232.00 to $250.00. They now have a “buy” rating on the stock.
• 1/22/2026 – Johnson & Johnson had its price target raised by analysts at Wells Fargo & Company from $230.00 to $240.00. They now have an “overweight” rating on the stock.
• 1/22/2026 – Johnson & Johnson had its price target raised by analysts at Leerink Partners from $201.00 to $232.00. They now have a “market perform” rating on the stock.
• 1/22/2026 – Johnson & Johnson had its price target raised by analysts at Bank of America Corporation from $220.00 to $221.00. They now have a “neutral” rating on the stock.
• 1/22/2026 – Johnson & Johnson had its price target raised by analysts at Scotiabank from $230.00 to $265.00. They now have a “sector outperform” rating on the stock.
• 1/22/2026 – Johnson & Johnson had its price target raised by analysts at Stifel Nicolaus from $205.00 to $220.00. They now have a “hold” rating on the stock.
• 1/17/2026 – Johnson & Johnson was downgraded by analysts at Wall Street Zen from a “buy” rating to a “hold” rating.
• 1/16/2026 – Johnson & Johnson was downgraded by analysts at Freedom Capital from a “strong-buy” rating to a “hold” rating.
• 1/9/2026 – Johnson & Johnson had its price target raised by analysts at Sanford C. Bernstein from $193.00 to $208.00. They now have a “market perform” rating on the stock.
• 1/5/2026 – Johnson & Johnson had its “buy” rating reaffirmed by analysts at UBS Group AG.
• 1/5/2026 – Johnson & Johnson had its price target raised by analysts at Wolfe Research from $225.00 to $240.00. They now have an “outperform” rating on the stock.
• 12/30/2025 – Johnson & Johnson had its price target raised by analysts at Barclays PLC from $197.00 to $217.00. They now have an “equal weight” rating on the stock.
• 12/18/2025 – Johnson & Johnson had its price target raised by analysts at The Goldman Sachs Group, Inc. from $213.00 to $240.00. They now have a “buy” rating on the stock.
• 12/17/2025 – Johnson & Johnson was given a new $240.00 price target on by analysts at Royal Bank Of Canada.
• 12/15/2025 – Johnson & Johnson had its price target raised by analysts at Bank of America Corporation from $204.00 to $220.00. They now have a “neutral” rating on the stock.
• 12/12/2025 – Johnson & Johnson had its price target raised by analysts at Morgan Stanley from $190.00 to $197.00. They now have an “equal weight” rating on the stock.
• 12/12/2025 – Johnson & Johnson had its price target raised by analysts at Wells Fargo & Company from $212.00 to $230.00. They now have an “overweight” rating on the stock.
• 12/11/2025 – Johnson & Johnson had its “outperform” rating reaffirmed by analysts at BMO Capital Markets.
• 12/11/2025 – Johnson & Johnson had its price target raised by analysts at Royal Bank Of Canada from $209.00 to $230.00. They now have an “outperform” rating on the stock.
• 12/11/2025 – Johnson & Johnson had its price target raised by analysts at Citigroup Inc. from $215.00 to $232.00. They now have a “buy” rating on the stock.

Johnson & Johnson Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Tuesday, February 24th will be given a $1.30 dividend. The ex-dividend date is Tuesday, February 24th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.2%. Johnson & Johnson’s payout ratio is 47.06%.

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.